In recent years, despite many research results in the field of immune cell infiltration in solid tumors and the development of immune checkpoint inhibitors such as anti-PD-1, CTLA-4 for the Treatment of Renal Cell Carcinoma, Metastatic Melanoma, and Non-Small Cell Lung Cancer(Tawbi et al., 2018). This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.